ClinicalTrials.gg
CompletedNCT02788474Updated Dec 21, 2023Results posted

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

A Phase 4 interventional study of nintedanib and placebo in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 86 sites in 13 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
347
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
2nd of 16
347 · median 49
Started
2016
with 2 others
Phase 4
5 of 16
none open now
Registered
7th of 16
by date
Lead sponsor
6 of 16
Boehringer Ingelheim

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 4, and was the 7th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consistent with International Conference on Harmonisation Good Clinical Practice and local laws, signed prior to participation in the trial including any study related procedures being performed;
  • Male or female patients aged >=40 years at Visit 1;
  • A clinical diagnosis of Idiopathic pulmonary fibrosis (IPF) within the last 3 years from visit 0, based upon the American Thoracic Society/ European Respiratory Society /Japanese Respiratory Society/ Latin American Thoracic Association 2011 guideline;
  • Chest high resolution computed tomography (HRCT) scan performed within 18 months of Visit 0;
  • Combination of HRCT pattern, and surgical lung pattern (the latter if available) as assessed by central review are consistent with the diagnosis of Idiopathic pulmonary fibrosis;
  • Forced vital capacity (FVC) >=80% of predicted normal at Visit 1.

Exclusion criteria

Exclusion criteria:

  • , Aspartate aminotransferase > 1.5 fold (ULN) at Visit 1;
  • Total > 1.5 fold ULN at Visit 1;
  • Patients with underlying chronic liver disease ( A, B or C hepatic impairment);
  • Relevant airways obstruction, i.e. pre-bronchodilator / Forced vital capacity \< 0.70;
  • History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of Visit 1;
  • Bleeding Risk:

    • Known genetic predisposition to bleeding;
    • Patients who require fibrinolysis, full-dose therapeutic anticoagulation or high dose antiplatelet therapy;
    • History of haemorrhagic central nervous system (CNS) event within 12 months prior to Visit 1;
    • History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to Visit 1;
    • (INR) > 2 at Visit 1;
    • Prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of ULN at Visit 1;
  • Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery;
  • History of thrombotic event (including stroke and ) within 12 months of Visit 1;
  • \< 30 mL/min calculated by Cockcroft-Gault formula at Visit 1;
  • Treatment with nintedanib, pirfenidone, azathioprine, cyclophosphamide, cyclosporine, any other drug, n-acetylcysteine, prednisone/prednisolone >15 mg daily or >30 mg every 2 days OR use of other systemic as well as any investigational drugs within 4 weeks of Visit 2;
  • Known to nintedanib, peanut, soya or to any other components of the study medication;
  • Prior discontinuation of nintedanib treatment due to intolerability/ adverse events considered drug related;
  • A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial;
  • Alcohol or drug abuse which in the opinion of the treating physician would interfere with the treatment and would affect patient's ability to participate in this trial;
  • Patients not able to understand and follow any study procedures such as but not limited to home spirometry, including completion of self-administered questionnaires without help;
  • Women who are pregnant, nursing, who plan to become pregnant while in the trial or female patients with positive pregnancy (ß-HCG) test at Visit 1 and/or Visit 2;
  • Women of childbearing potential4 not willing or able to use highly effective methods of per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
  • Patients with acute IPF exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 or during the screening period;
  • Patients who are or have been participating in another trial with investigational drug/s within one month prior to Visit 1 and patients who have previously been enrolled in this trial;
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
347 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Experimental
    nintedanib

    Drug: nintedanib

Interventions

06

What researchers measure

Primary outcomes

  1. The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.

    The rate of change (slope) in blood C-reactive protein degraded by matrix metalloproteinase-1/8 (CRPM) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (CRPM log 10 transformed) with fixed effects for gender, age, height and random effect of patient specific intercept and time.

    Time frame: baseline and 12 weeks

Secondary outcomes

  1. Percentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 52

    For this endpoint, disease progression was defined by absolute FVC (percentage of predicted) decline ≥10% or death up to Week 52 based on in-clinic supervised spirometry. This is a key secondary endpoint of the trial. This outcome measure is "percentage of patients with disease progression" and CRPM is included in the various models as a factor/covariate, and that this outcome measure, the percentage of progressors are displayed under "Measured values"

    Time frame: 52 weeks

  2. The Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 12

    The rate of change in blood Collagen 1 degraded by matrix metalloproteinase-2/9/13 (C1M) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (C1M (negative reciprocal root transformation)) with fixed effects for gender, age, height and random effect of patient specific intercept and time.

    Time frame: baseline and 12 weeks

  3. The Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12

    The rate of change in blood Collagen 3 degraded by matrix metalloproteinase-9 (C3M) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (C3M- log 10 transformation) with fixed effects for gender, age, height and random effect of patient specific intercept and time.

    Time frame: baseline and 12 weeks

07

Results

Posted Aug 6, 2019

Participant flow

The trial comprised of 2 treatment periods (52 weeks). The first treatment period was a 12-week, randomised, double-blind, placebo-controlled, parallel-group period whereas the second treatment period was a 40-week, single-arm, open-label, active treatment (nintedanib 150 milligram (mg) twice daily (bid)) period.

Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
MilestonePlacebo/ NintedanibNintedanib/ Nintedanib
Started231116
Treated230116
Completed221112
Not completed104
Withdrew: Not treated10
Withdrew: Patient's refusal30
Withdrew: Adverse event64
Open Label Treatment Period
Participant flow — Open Label Treatment Period
MilestonePlacebo/ NintedanibNintedanib/ Nintedanib
Started221112
Completed189100
Not completed3212
Withdrew: Adverse event299
Withdrew: Other than reason specified10
Withdrew: Patient's refusal13
Withdrew: Non-compliance10

Outcome measures

PrimaryThe Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.

The rate of change (slope) in blood C-reactive protein degraded by matrix metalloproteinase-1/8 (CRPM) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (CRPM log 10 transformed) with fixed effects for gender, age, height and random effect of patient specific intercept and time.

Time frame:
baseline and 12 weeks
Reported as:
Mean · nanogram/ millitre/ month (ng/ mL/ mth)
The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.
nanogram/ millitre/ month (ng/ mL/ mth)Placebo/ NintedanibNintedanib/ Nintedanib
The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.-0.00190 ± 0.00165-0.00257 ± 0.00232
Statistical analysis
  • Placebo/ Nintedanib vs Nintedanib/ Nintedanib · random coefficient regression · p = 0.8146 (random coefficient regression (random slopes and intercepts) model including sex, age and height as covariates (Due to the low number of measurements per patient, baseline CRPM was included as a response rather than as a covariate in the analysis)) · Adjusted mean difference: -0.00066 · 95% CI -0.00621 to 0.00488Difference calculated as Nintedanib minus Placebo
SecondaryPercentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 52

For this endpoint, disease progression was defined by absolute FVC (percentage of predicted) decline ≥10% or death up to Week 52 based on in-clinic supervised spirometry. This is a key secondary endpoint of the trial. This outcome measure is "percentage of patients with disease progression" and CRPM is included in the various models as a factor/covariate, and that this outcome measure, the percentage of progressors are displayed under "Measured values"

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 52
Percentage of participantsPlacebo/ NintedanibNintedanib/ Nintedanib
Percentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 5230.43 (24.85 to 36.66)25.00 (18.01 to 33.60)
Statistical analysis
  • Placebo/ Nintedanib · Regression, Logistic · p = 0.2084 · Slope estimate: 22.001 · 95% CI -11.83 to 57.58Slope estimate is the monthly rate of change in CRPM up to week 12
  • Placebo/ Nintedanib vs Nintedanib/ Nintedanib · Regression, Logistic · p = 0.1537 · Slope estimate: -45.566 · 95% CI -109.55 to 16.37Slope estimate is the monthly rate of change in CRPM up to week 12
  • Placebo/ Nintedanib vs Nintedanib/ Nintedanib · Regression, Logistic · p = 0.3116 · Odds ratio (or): 0.769 · 95% CI 0.46 to 1.27
  • Placebo/ Nintedanib vs Nintedanib/ Nintedanib · Regression, Logistic · p = 0.3175 · Odds ratio (or): 0.772 · 95% CI 0.46 to 1.27
SecondaryThe Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 12

The rate of change in blood Collagen 1 degraded by matrix metalloproteinase-2/9/13 (C1M) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (C1M (negative reciprocal root transformation)) with fixed effects for gender, age, height and random effect of patient specific intercept and time.

Time frame:
baseline and 12 weeks
Reported as:
Mean · ng/ml/mth
The Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 12
ng/ml/mthPlacebo/ NintedanibNintedanib/ Nintedanib
The Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 120.00041 ± 0.001270.00162 ± 0.00172
Statistical analysis
  • Placebo/ Nintedanib vs Nintedanib/ Nintedanib · random coefficient regression · p = 0.5469 (random coefficient regression model (C1M (negative reciprocal root-transformed)) with fixed effects for gender, age, height and random effect of patient specific intercept and time.) · Adjusted mean difference: 0.00121 · 95% CI -0.00273 to 0.00515Difference calculated as Nintedanib minus Placebo. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix.
SecondaryThe Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12

The rate of change in blood Collagen 3 degraded by matrix metalloproteinase-9 (C3M) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (C3M- log 10 transformation) with fixed effects for gender, age, height and random effect of patient specific intercept and time.

Time frame:
baseline and 12 weeks
Reported as:
Mean · ng/ml/mth
The Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12
ng/ml/mthPlacebo/ NintedanibNintedanib/ Nintedanib
The Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12-0.00091 ± 0.00158-0.00398 ± 0.00219
Statistical analysis
  • Placebo/ Nintedanib vs Nintedanib/ Nintedanib · random coefficient regression · p = 0.2429 (random coefficient regression model (C3M (log10-transformed)) with fixed effects for gender, age, height and random effect of patient specific intercept and time.) · Adjusted mean difference: -0.00307 · 95% CI -0.00823 to 0.00209Difference calculated as Nintedanib minus Placebo. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix.

Adverse events

Collected over Serious Adverse Event (SAE) & Non SAE: All adverse events (AEs) that occurred between first drug intake and 28 days after last drug intake (end of the Residual effect period (REP)); up to 53 weeks All cause mortality: All AEs during the course of the clinical trial; up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double Blind Period)0/230 (0%)18/230 (7.8%)103/230 (44.8%)
Nintedanib (Double Blind Period)0/116 (0%)8/116 (6.9%)80/116 (69%)
Nintedanib (Open Label Period)9/333 (2.7%)65/333 (19.5%)277/333 (83.2%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventPlacebo (Double Blind Period)Nintedanib (Double Blind Period)Nintedanib (Open Label Period)
PneumoniaInfections and infestations1/2300/1165/333
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/2301/1165/333
Lower respiratory tract infectionInfections and infestations2/2300/1162/333
Hypertensive crisisVascular disorders2/2301/1161/333
GlaucomaEye disorders1/2301/1162/333
Inguinal herniaGastrointestinal disorders0/2301/1160/333
ConcussionInjury, poisoning and procedural complications0/2301/1160/333
FallInjury, poisoning and procedural complications0/2301/1162/333
Jaw fractureInjury, poisoning and procedural complications0/2301/1160/333
Chondrocalcinosis pyrophosphateMusculoskeletal and connective tissue disorders0/2301/1160/333
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo (Double Blind Period)Nintedanib (Double Blind Period)Nintedanib (Open Label Period)
DiarrhoeaGastrointestinal disorders42/23054/116215/333
NauseaGastrointestinal disorders15/23017/11657/333
NasopharyngitisInfections and infestations19/23010/11649/333
VomitingGastrointestinal disorders7/2309/11642/333
Decreased appetiteMetabolism and nutrition disorders10/23012/11639/333
CoughRespiratory, thoracic and mediastinal disorders16/2305/11638/333
Weight decreasedInvestigations2/2306/11626/333
Back painMusculoskeletal and connective tissue disorders5/2303/11624/333
BronchitisInfections and infestations5/2303/11623/333
Alanine aminotransferase increasedInvestigations2/2307/11617/333

Baseline characteristics

Treated Set (TS), consisting of participants who were randomised to a treatment group and received at least one dose of trial medication

Age, Continuous
Age, Continuous(years)Placebo/ NintedanibNintedanib/ NintedanibTotal
Mean70.2 ± 7.270.5 ± 7.770.3 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/ NintedanibNintedanib/ NintedanibTotal
Female612384
Male16993262
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/ NintedanibNintedanib/ NintedanibTotal
Hispanic or Latino19928
Not Hispanic or Latino19396289
Unknown or Not Reported181129
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/ NintedanibNintedanib/ NintedanibTotal
American Indian or Alaska Native000
Asian6835103
Native Hawaiian or Other Pacific Islander000
Black or African American000
White14470214
More than one race000
Unknown or Not Reported181129
08

Study locations

86 sites
  • Jasper Summit Research, LLC
    Jasper, Alabama 35501, United States
  • Western Connecticut Medical Group
    Danbury, Connecticut 06810, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • University of Florida College of Medicine
    Jacksonville, Florida 32209, United States
  • Minnesota Lung Center
    Minneapolis, Minnesota 55407, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Clinical Research Solutions
    Dayton, Ohio 45409, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23225, United States
  • Royal Prince Alfred Hospital
    Camperdown, Sydney, New South Wales 2050, Australia
  • Concord General Repatriation Hospital -Ambulatory Care Unit
    Concord, New South Wales 2139, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • ULB Hopital Erasme
    Bruxelles, 1070, Belgium
  • Edegem - UNIV UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Yvoir - UNIV UCL de Mont-Godinne
    Yvoir, 5530, Belgium
  • University Hospital Olomouc
    Olomouc, 779 00, Czechia
  • University Hospital Plzen, Plzen-Bory
    Plzen, 30599, Czechia
  • Thomayer Hospital
    Praha 4, 14059, Czechia
  • University Hospital Na Bulovce, Prague
    Praha, 180 81, Czechia
  • Masaryk Hospital, Usti nad Labem
    Usti nad Labem, 401 13, Czechia
  • HYKS Keuhkosairauksien
    Helsinki, 00290, Finland
  • KYS, Keuhkosairauksien
    Kuopio, 70210, Finland
  • OYS, sisätautien klinikka
    Oulu, 90220, Finland
  • Tampere University Hospital
    Tampere, FI-33520, Finland
  • TYKS, Keuhkosairauksien klinikka, Turku
    Turku, 20520, Finland
  • HOP de la Cavale Blanche
    Brest, 29609, France
  • HOP Louis Pradel
    Bron, 69677, France
  • HOP Européen G. Pompidou
    Paris, 75015, France
  • HOP Maison Blanche
    Reims Cedex, 51092, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • HOP Civil
    Strasbourg, 67091, France
  • HOP Bretonneau
    Tours, 37044, France
  • CIMS Studienzentrum Bamberg GmbH
    Bamberg, 96049, Germany
  • Helios Klinikum Emil von Behring
    Berlin, 14165, Germany
  • Universitätsklinikum Gießen und Marburg GmbH
    Gießen, 35392, Germany
  • Universitätsmedizin Greifswald
    Greifswald, 17475, Germany
  • Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
    Grosshansdorf, 22927, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • Klinikum der Universität München - Campus Großhadern
    München, 81377, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Semmelweis University
    Budapest, 1125, Hungary
  • Csongrad County's Hosp.
    Deszk, 6772, Hungary
  • Pulmonology Institute of Veszprem County, Farkasgyepu
    Farkasgyepu, 8582, Hungary
  • BAZ County Central Hospital and University Teaching Hospital
    Miskolc, 3526, Hungary
  • Tosei General Hospital
    Aichi, Seto, 489-8642, Japan
  • Kurume University Hospital
    Fukuoka, Kurume, 830-0011, Japan
  • Ibarakihigashi National Hospial
    Ibaraki, Naka-gun, 319-1113, Japan
  • Kanagawa Cardiovascular and Respiratory Center
    Kanagawa, Yokohama, 236-0051, Japan
  • Kindai University Hospital
    Osaka, Osakasayama, 589-8511, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Osaka, Sakai, 591-8555, Japan
  • Tokushima University Hospital
    Tokushima, Tokushima, 770-8503, Japan
  • Nippon Medical School Hospital
    Tokyo, Bunkyo-ku, 113-8603, Japan
  • Toho University Omori Medical Center
    Tokyo, Ota-ku, 143-8541, Japan
  • Global Health and Medicine Ctr
    Tokyo, Shinjuku-ku, 162-8655, Japan
  • Seoul National University Bundang Hospital
    Seongnam, 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Our Doctor Clinical Trial Center, Department in Bydgoszcz
    Bydgoszcz, 85065, Poland
  • Non-pub.Health Care NZOZ Profilaktyka W. Pierzchala,Katowice
    Katowice, 40-752, Poland
  • Univ. Hospital in Krakow,Pulmonology Clinical Dept
    Krakow, 31-066, Poland
  • John Paul II Cracovian Hosp
    Krakow, 31-202, Poland
  • Norbert Barlicki University Clinical Hospital No.1, Lodz
    Lodz, 90-153, Poland
  • Practice of Internists "Nasz Lekarz", Torun
    Torun, 87-100, Poland
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital de Galdakao
    Galdakao, 48960, Spain
  • Hospital de Bellvitge
    L'Hospitalet Llobregat (bcn), 08907, Spain
  • Hospital La Princesa
    Madrid, 28006, Spain
  • Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Puerta de Hierro
    Majadahonda (Madrid), 28220, Spain
  • Hospital Quirónsalud Madrid
    Pozuelo de Alarcón, 28223, Spain
  • CS Parc Taulí
    Sabadell, 08208, Spain
  • Hospital Virgen del Rocío
    Sevilla, 41013, Spain
  • Hospital Clínico de Valencia
    Valencia, 46010, Spain
  • Hospital Dr. Peset
    Valencia, 46017, Spain
  • Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
  • Papworth Hospital
    Cambridge, CB23 3RE, United Kingdom
  • Royal Devon and Exeter Hospital
    Exeter, EX2 5DW, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y. PubMed 33902584 ↗
  • Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, Jouneau S, Michael A, Quaresma M, Rohr KB, Russell AM, Stowasser S, Maher TM; INMARK trial investigators. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J. 2021 Jul 8;58(1):2001518. doi: 10.1183/13993003.01518-2020. Print 2021 Jul. PubMed 33419890 ↗
  • Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. Epub 2019 Jul 17. PubMed 31326319 ↗
  • Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK(R)trial. BMJ Open Respir Res. 2018 Aug 20;5(1):e000325. doi: 10.1136/bmjresp-2018-000325. eCollection 2018. PubMed 30167310 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Aug 2017, 13 months.

Results were first posted in Aug 2019, 2 years after primary completion. A results delay was requested in May 2018.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2016
First posted
Jun 2, 2016
StartActual
Jun 9, 2016
Primary completionActual
Aug 4, 2017
CompletionActual
Jun 8, 2018
Results delay requested
May 17, 2018
Results first posted
Aug 6, 2019
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02788474
Responsible party
Sponsor
First posted
Jun 2, 2016
Start date
Jun 9, 2016
Primary completion
Aug 4, 2017
Completion
Jun 8, 2018
Results posted
Aug 6, 2019
Last update
Dec 21, 2023

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion